Sort by

Date

Institutional score

Impact

Patients

List order

Sort

Categories

Studies

100 Case Reports

66 Reviews

48 Unclassified

39 Research

27 Early Trials

20 Other Trials

8 Advanced Trials

Guidelines

Congresses

23 Abstracts

1

Research

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Cools Jan, Quentmeier Hilmar, Huntly Brian J P, Marynen Peter, Griffin James D ...

Blood Vol 103(7)

Read

Date 01 Apr 2004

Institutional score
232.44
Impact
144.67

Add to library

Add to library

Select a folder

Create a new folder +

Cancel

Date 01 Apr 2004

Institutional score
232.44
Impact
144.67
2

Research

FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome.

Yamada Yoshiyuki, Sanchez-Aguilera Abel, Brandt Eric B, McBride Melissa, Al-Moamen Nabeel J H ...

Blood Vol 112(6)

Read

Date 15 Sep 2008

Institutional score
19.68
Impact
144.67

Add to library

Add to library

Select a folder

Create a new folder +

Cancel

Date 15 Sep 2008

Institutional score
19.68
Impact
144.67
3

Research

The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.

Yamada Yoshiyuki, Rothenberg Marc E, Lee Andrew W, Akei Hiroko Saito, Brandt Eric B ...

Blood Vol 107(10)

Read

Date 15 May 2006

Institutional score
19.68
Impact
144.67

Add to library

Add to library

Select a folder

Create a new folder +

Cancel

Date 15 May 2006

Institutional score
19.68
Impact
144.67
4

Research

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-posi...

Jovanovic Jelena V, Score Joannah, Waghorn Katherine, Cilloni Daniela, Gottardi Enrico ...

Blood Vol 109(11)

Read

Date 01 Jun 2007

Institutional score
0.00
Impact
144.67

Add to library

Add to library

Select a folder

Create a new folder +

Cancel

Date 01 Jun 2007

Institutional score
0.00
Impact
144.67
5

Research

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

Lierman Els, Folens Cedric, Stover Elizabeth H, Mentens Nicole, Van Miegroet Helen ...

Blood Vol 108(4)

Read

Date 15 Aug 2006

Institutional score
38.74
Impact
144.67

Add to library

Add to library

Select a folder

Create a new folder +

Cancel

Date 15 Aug 2006

Institutional score
38.74
Impact
144.67
6

Research

Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.

Stover Elizabeth H, Chen Jing, Folens Cedric, Lee Benjamin H, Mentens Nicole ...

Proceedings of the National Academy of Sciences of the United States o... Vol 103(21)

Read

Date 23 May 2006

Institutional score
116.22
Impact
128.92

Add to library

Add to library

Select a folder

Create a new folder +

Cancel

Date 23 May 2006

Institutional score
116.22
Impact
128.92
7

Research

WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.

Cilloni D, Messa F, Martinelli G, Gottardi E, Arruga F ...

Leukemia Vol 21(7)

Read

Date 01 Jul 2007

Institutional score
0.00
Impact
94.87

Add to library

Add to library

Select a folder

Create a new folder +

Cancel

Date 01 Jul 2007

Institutional score
0.00
Impact
94.87
8

Research

TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia.

Rosati R, La Starza R, Luciano L, Gorello P, Matteucci C ...

Leukemia Vol 20(9)

Read

Date 01 Sep 2006

Institutional score
0.00
Impact
94.87

Add to library

Add to library

Select a folder

Create a new folder +

Cancel

Date 01 Sep 2006

Institutional score
0.00
Impact
94.87
9

Research

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.

Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M ...

Leukemia Vol 26(1)

Read

Date 01 Jan 2012

Institutional score
0.00
Impact
94.87

Add to library

Add to library

Select a folder

Create a new folder +

Cancel

Date 01 Jan 2012

Institutional score
0.00
Impact
94.87
10

Research

Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia.

Cross Nicholas C P, Hoade Yvette, Tapper William J, Carreno-Tarragona Gonzalo, Fanelli Tiziana ...

Leukemia Vol 33(2)

Read

Date 01 Feb 2019

Institutional score
323.39
Impact
94.87

Add to library

Add to library

Select a folder

Create a new folder +

Cancel

Date 01 Feb 2019

Institutional score
323.39
Impact
94.87

View

per page

Page

1

2

3

4

Last